Marinus Pharmaceuticals Approves Senior Management Retention and Change in Control Severance PlansOn December 17, 2024, Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) announced the approval of a retention plan for senior management and an amendment to t

by · The Cerbat Gem

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Marinus Pharmaceuticals’s 8K filing here.

About Marinus Pharmaceuticals

(Get Free Report)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

See Also